BACKGROUND: GLP-1 agonists, including liraglutide, have emerged as effective therapies for type 2 diabetes (DM) and obesity. Here, we attempted to delineate how liraglutide, at doses approved for DM, may impact circulating hormones influencing energy homeostasis in diabetics. BASIC PROCEDURES: Using a randomized, placebo-controlled, double-blind, cross-over trial of 20 patients with type 2 diabetes, we examined the effects of liraglutide as compared to placebo on fasting levels of circulating hormones important to energy homeostasis, including leptin, ghrelin, PYY, and GIP. After 17days (0.6mg for 7days, 1.2mg for 7days and 1.8mg for 3days) of treatment, we also studied changes in fMRI responses to food cues. MAIN FINDINGS: By design, to avoid any confounding by weight changes, subjects were studied for 17days, i.e. before body weight changed. Participants on liraglutide had significantly increased GLP-1 levels (p<0.001), decreased percent change in leptin levels (p<0.01) and increased GIP levels (p<0.03) in comparison to placebo treated subjects. Whole brain regressions of functional activity in response to food cues reveal that increased GIP levels were associated with deactivation of the attention- and reward-related insula. Decreases in leptin levels were associated with activations in the reward-related midbrain, precuneus, and dorsolateral prefrontal cortex (DLPFC), and sensorimotor-related motor cortex and with deactivations in the attention-related parietal cortex and the cognitive control-related thalamus and pre-SMA. PRINCIPAL CONCLUSIONS: We demonstrate herein short-term changes to circulating levels of GIP and leptin in response to GLP-1 agonist liraglutide therapy. These findings suggest that liraglutide may alter the circulating levels of hormones important in energy homeostasis that, in turn, influence CNS perception of food cues. This could possibly lead to compensatory changes in energy homeostasis that could over time limit the efficacy of liraglutide to decrease body weight. These novel findings, which, pointing to the potential advantages of combination therapies, may have therapeutic implications, will need to be confirmed by larger and longer-term trials.
RCT Entities:
BACKGROUND:GLP-1 agonists, including liraglutide, have emerged as effective therapies for type 2 diabetes (DM) and obesity. Here, we attempted to delineate how liraglutide, at doses approved for DM, may impact circulating hormones influencing energy homeostasis in diabetics. BASIC PROCEDURES: Using a randomized, placebo-controlled, double-blind, cross-over trial of 20 patients with type 2 diabetes, we examined the effects of liraglutide as compared to placebo on fasting levels of circulating hormones important to energy homeostasis, including leptin, ghrelin, PYY, and GIP. After 17days (0.6mg for 7days, 1.2mg for 7days and 1.8mg for 3days) of treatment, we also studied changes in fMRI responses to food cues. MAIN FINDINGS: By design, to avoid any confounding by weight changes, subjects were studied for 17days, i.e. before body weight changed. Participants on liraglutide had significantly increased GLP-1 levels (p<0.001), decreased percent change in leptin levels (p<0.01) and increased GIP levels (p<0.03) in comparison to placebo treated subjects. Whole brain regressions of functional activity in response to food cues reveal that increased GIP levels were associated with deactivation of the attention- and reward-related insula. Decreases in leptin levels were associated with activations in the reward-related midbrain, precuneus, and dorsolateral prefrontal cortex (DLPFC), and sensorimotor-related motor cortex and with deactivations in the attention-related parietal cortex and the cognitive control-related thalamus and pre-SMA. PRINCIPAL CONCLUSIONS: We demonstrate herein short-term changes to circulating levels of GIP and leptin in response to GLP-1 agonist liraglutide therapy. These findings suggest that liraglutide may alter the circulating levels of hormones important in energy homeostasis that, in turn, influence CNS perception of food cues. This could possibly lead to compensatory changes in energy homeostasis that could over time limit the efficacy of liraglutide to decrease body weight. These novel findings, which, pointing to the potential advantages of combination therapies, may have therapeutic implications, will need to be confirmed by larger and longer-term trials.
Authors: J P Gutzwiller; B Göke; J Drewe; P Hildebrand; S Ketterer; D Handschin; R Winterhalder; D Conen; C Beglinger Journal: Gut Date: 1999-01 Impact factor: 23.059
Authors: Kristina M Rapuano; Jeremy F Huckins; James D Sargent; Todd F Heatherton; William M Kelley Journal: Cereb Cortex Date: 2015-05-20 Impact factor: 5.357
Authors: Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad Journal: Diabetes Care Date: 2007-03-19 Impact factor: 19.112
Authors: O M Farr; B-J Ko; K E Joung; L Zaichenko; N Usher; M Tsoukas; B Thakkar; C R Davis; J A Crowell; C S Mantzoros Journal: Nutr Metab Cardiovasc Dis Date: 2015-02-03 Impact factor: 4.222
Authors: Nikolaos Mentis; Irfan Vardarli; Lars D Köthe; Jens J Holst; Carolyn F Deacon; Michael Theodorakis; Juris J Meier; Michael A Nauck Journal: Diabetes Date: 2011-02-17 Impact factor: 9.461
Authors: Olivia M Farr; Jagriti Upadhyay; Chelsea Rutagengwa; Bridget DiPrisco; Zachary Ranta; Amal Adra; Neha Bapatla; Vivian P Douglas; Konstantinos A A Douglas; Eric Nolen-Doerr; Hannah Mathew; Christos S Mantzoros Journal: Diabetes Obes Metab Date: 2019-08-08 Impact factor: 6.577
Authors: J Góralska; U Raźny; A Polus; J Stancel-Możwiłło; M Chojnacka; A Gruca; A Zdzienicka; A Dembińska-Kieć; B Kieć-Wilk; B Solnica; M Malczewska-Malec Journal: Int J Obes (Lond) Date: 2017-12-13 Impact factor: 5.095
Authors: Ji A Seo; Min-Cheol Kang; Theodore P Ciaraldi; Sang Soo Kim; Kyong Soo Park; Charles Choe; Won Min Hwang; Dong Mee Lim; Olivia Farr; Christos Mantzoros; Robert R Henry; Young-Bum Kim Journal: Metabolism Date: 2017-10-03 Impact factor: 8.694
Authors: Hoda Kadouh; Victor Chedid; Houssam Halawi; Duane D Burton; Matthew M Clark; Disha Khemani; Adrian Vella; Andres Acosta; Michael Camilleri Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958